Clearly, measuring PITX2 expression in atrial tissue of people who are not candidates for surgery is impracticable, so surrogate blood biomarkers of PITX could be used to subtype AF patient populations to bring about much‐needed leaps in personalised predictions of both AF risk and response to therapy. The gene discussed is PITX2; the disease is atrial fibrillation.